| Danny Eisenberg, MD | |
|
1906 Blake Ave, Glenwood Springs, CO 81601-4227 | |
| (970) 447-4065 | |
| Not Available |
| Full Name | Danny Eisenberg |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 47 Years |
| Location | 1906 Blake Ave, Glenwood Springs, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376594978 | NPI | - | NPPES |
| NV3798 | Other | NV | BCBS |
| NV4882 | Other | NV | BCBS |
| 200290012 | Medicaid | NV | |
| 153101 | Other | NV | WC |
| 152973 | Other | NV | WC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 6719 (Nevada) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southwest General Health Center | Middleburg heights, OH | Hospital |
| Piedmont Columbus Regional Midtown | Columbus, GA | Hospital |
| Carolina East Medical Center | New bern, NC | Hospital |
| Piedmont Columbus Regional Northside | Columbus, GA | Hospital |
| Onslow Memorial Hospital | Jacksonville, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eagle Partners Pllc | 9032205752 | 92 |
| Greensboro Radiology Pa | 8729074901 | 207 |
| Imaging Associates Of New Mexico Llc | 4981970233 | 97 |
| Northside Radiology Associates Llc | 4486555398 | 213 |
| Radiology Associates Of Southwest Louisiana | 0941243562 | 94 |
| Singleton Associates Pa | 6305731118 | 691 |
| Radiology Associates Of Southwest Louisiana | 0941243562 | 94 |
| Eagle Partners Pllc | 9032205752 | 92 |
| Greensboro Radiology Pa | 8729074901 | 207 |
| Imaging Associates Of New Mexico Llc | 4981970233 | 97 |
| Singleton Associates Pa | 6305731118 | 691 |
| Columbus Radiology Corp | 6507754983 | 271 |
| Eagle Partners Pllc | 9032205752 | 92 |
| Greensboro Radiology Pa | 8729074901 | 207 |
| Imaging Associates Of New Mexico Llc | 4981970233 | 97 |
| Northside Radiology Associates Llc | 4486555398 | 213 |
| Singleton Associates Pa | 6305731118 | 691 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Ellis Bandt Birkin Kollins & Wong Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578584678 PECOS PAC ID: 4486568946 Enrollment ID: O20031118000697 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Imaging Associates Of Michigan Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164943007 PECOS PAC ID: 9537434386 Enrollment ID: O20190108000997 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Imaging Associates Of New Mexico Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629592464 PECOS PAC ID: 4981970233 Enrollment ID: O20190111000178 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Southwest Diagnostic Imaging Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902896236 PECOS PAC ID: 7416946199 Enrollment ID: O20190214000707 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Renaissance Imaging Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487608931 PECOS PAC ID: 7315841756 Enrollment ID: O20190404002873 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Radiology Affiliates Of Central New Jersey P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811994791 PECOS PAC ID: 1759277239 Enrollment ID: O20190620002872 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Singleton Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538107875 PECOS PAC ID: 6305731118 Enrollment ID: O20190702003178 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Radiology Associates Of Southwest Louisiana |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033215710 PECOS PAC ID: 0941243562 Enrollment ID: O20200423000538 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Greensboro Radiology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821035999 PECOS PAC ID: 8729074901 Enrollment ID: O20200720001310 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Northside Radiology Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013960657 PECOS PAC ID: 4486555398 Enrollment ID: O20200901001126 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Golden State Imaging Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144872052 PECOS PAC ID: 1254761315 Enrollment ID: O20200916002103 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Specialists In Medical Imaging Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841687951 PECOS PAC ID: 2163733544 Enrollment ID: O20201001001378 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Sonoran Radiology Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033745708 PECOS PAC ID: 3375964505 Enrollment ID: O20201111002372 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Mountain Radiology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093823742 PECOS PAC ID: 4688666761 Enrollment ID: O20210604000152 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Entity Name | Eagle Partners Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548450976 PECOS PAC ID: 9032205752 Enrollment ID: O20221006002503 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Danny Eisenberg, MD Po Box 30077, Dept 305, Salt Lake City, UT 84130-0077 Ph: (877) 243-8416 | Danny Eisenberg, MD 1906 Blake Ave, Glenwood Springs, CO 81601-4227 Ph: (970) 447-4065 |
News Archive
Kaiser Permanente, one of the country's largest not-for-profit health plans, has been recognized as a "Best Place to Work" by three publications. In the first half of 2010, the organization was ranked No. 1 by Diversity MBA Magazine for diverse managers, and No. 2 in the San Francisco Business Times' list of "Best Places to Work."
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers."
MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.
› Verified 7 days ago
Nia Kimberly Sawyer, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1906 Blake Ave, Glenwood Springs, CO 81601 Phone: 970-447-4065 | |
Michael M Hovsepian, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1906 Blake Ave, Glenwood Springs, CO 81601 Phone: 970-447-4065 | |
Dr. Joel A Shockley, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1906 Blake Ave, Glenwood Springs, CO 81601 Phone: 970-447-4065 | |
Harold D Young, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 504 21st St, Glenwood Springs, CO 81601 Phone: 970-945-7564 Fax: 970-945-0563 | |
Samuel Song, Radiology Medicare: Accepting Medicare Assignments Practice Location: 1906 Blake Ave, Glenwood Springs, CO 81601 Phone: 970-447-4065 | |
Dr. Jason Fox, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1906 Blake Ave, Glenwood Springs, CO 81601 Phone: 970-447-4065 | |
Dr. Elena Motuzko, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1906 Blake Avenue, Glenwood Springs, CO 81601 Phone: 970-945-7564 Fax: 970-945-0563 |